Sanofi - Product Pipeline Review - 2016

Published: Apr, 2016 | Pages: 203 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sanofi - Product Pipeline Review - 2016

Summary

Global Markets Direct's, ‘Sanofi - Product Pipeline Review - 2016', provides an overview of the Sanofi's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Sanofi, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sanofi
- The report provides overview of Sanofi including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Sanofi's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Sanofi's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Sanofi's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sanofi
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sanofi's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
Sanofi Snapshot 6
Sanofi Overview 6
Key Information 6
Key Facts 6
Sanofi - Research and Development Overview 7
Key Therapeutic Areas 7
Sanofi - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 19
Sanofi - Pipeline Products Glance 21
Sanofi - Late Stage Pipeline Products 21
Sanofi - Clinical Stage Pipeline Products 24
Sanofi - Early Stage Pipeline Products 26
Sanofi - Drug Profiles 28
(insulin glargine + lixisenatide) 28
lixisenatide 31
mipomersen sodium 35
semuloparin sodium 37
(fexofenadine hydrochloride + phenylephrine hydrochloride) 38
avanafil 39
cabazitaxel 40
insulin lispro 42
ziv-aflibercept (recombinant) 43
fexinidazole 47
(capecitabine + cyclophosphamide) 49
alemtuzumab 50
artefenomel + ferroquine 53
ataciguat 55
efpeglenatide 56
isatuximab 58
plerixafor 60
SAR-156597 63
sotagliflozin 64
pilaralisib 66
SAR-408701 69
SAR-421869 70
SAR-422459 72
voxtalisib 74
Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease 76
SAR-113244 77
SAR-228810 78
SAR-366234 79
SAR-407899 80
SAR-425899 81
SAR-428926 82
SAR-438335 83
SAR-438544 84
SAR-440067 85
SAR-566658 86
ACP-003 88
DCM-1 89
efpeglenatide + HM-12470 90
food allergy vaccine 91
Peptides for Tuberculosis 92
Recombinant Proteins for Pseudomonas aeruginosa Infection 93
SAR-088 95
SAR-110068 96
SAR-131675 97
SAR-156497 98
SAR-184841 99
SAR-216471 100
SAR-224 101
SAR-244181 102
SAR-296968 103
SAR-396049 104
SAR-7334 105
Small Molecule 4 for Tuberculosis 106
Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis 107
Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds 108
Monoclonal Antibodies for Infectious Disease 109
Monoclonal Antibodies for Neurodegenerative Diseases 110
Peptide for HIV and HSV Infections 111
SAR-405 112
Small Molecule 2 for Tuberculosis 113
Small Molecule 3 for Tuberculosis 114
Small Molecule for Calcific Aortic Valve Stenosis 115
Small Molecule for Duchenne Muscular Dystrophy 116
Small Molecules for Malaria 117
Small Molecules to Inhibit Protein Kinase for Undisclosed Indication 118
Vaccine for Celiac Disease 119
Vaccine for Food Allegy 2 120
Zika virus vaccine 121
Sanofi - Pipeline Analysis 122
Sanofi - Pipeline Products by Target 122
Sanofi - Pipeline Products by Route of Administration 126
Sanofi - Pipeline Products by Molecule Type 127
Sanofi - Pipeline Products by Mechanism of Action 128
Sanofi - Recent Pipeline Updates 131
Sanofi - Dormant Projects 161
Sanofi - Discontinued Pipeline Products 165
Discontinued Pipeline Product Profiles 167
Sanofi - Company Statement 178
Sanofi - Locations And Subsidiaries 179
Head Office 179
Other Locations & Subsidiaries 179
Sanofi - Key Manufacturing Facilities 194
Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 195
Disclaimer 196

List of Tables

Sanofi, Key Information 13
Sanofi, Key Facts 13
Sanofi - Pipeline by Indication, 2016 15
Sanofi - Pipeline by Stage of Development, 2016 20
Sanofi - Monotherapy Products in Pipeline, 2016 21
Sanofi - Combination Treatment Modalities in Pipeline, 2016 22
Sanofi - Partnered Products in Pipeline, 2016 23
Sanofi - Partnered Products/ Combination Treatment Modalities, 2016 24
Sanofi - Out-Licensed Products in Pipeline, 2016 26
Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2016 27
Sanofi - Pre-Registration, 2016 28
Sanofi - Filing rejected/Withdrawn, 2016 29
Sanofi - Phase III, 2016 30
Sanofi - Phase II, 2016 31
Sanofi - Phase I, 2016 32
Sanofi - Preclinical, 2016 33
Sanofi - Discovery, 2016 34
Sanofi - Pipeline by Target, 2016 129
Sanofi - Pipeline by Route of Administration, 2016 133
Sanofi - Pipeline by Molecule Type, 2016 134
Sanofi - Pipeline Products by Mechanism of Action, 2016 135
Sanofi - Recent Pipeline Updates, 2016 138
Sanofi - Dormant Developmental Projects,2016 168
Sanofi - Discontinued Pipeline Products, 2016 172
Sanofi, Subsidiaries 186
Sanofi, Key Manufacturing Facilities 201